Viking Therapeutics, Inc.

VKTX Nasdaq SEC CIK 1607678
Follow Viking Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $0
Net income −$183.2M −101.8% vs same quarter last year
EPS, diluted −$1.55 −91.4% vs same quarter last year
Operating cash flow −$138.2M −47% vs same quarter last year
Revenue by quarter
$0
$0
$0
$0
$0
$0
$0
$0
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income13 fiscal years
  • Revenue
  • Net income
−$400M−$300M−$200M−$100M$0FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$0−$359.6M
FY24$0−$110M
FY23$0−$85.9M
FY22$0−$68.9M
FY21$0−$55M
FY20$0−$39.5M
FY19$0−$25.8M
FY18$0−$22.1M
FY17$0−$20.6M
FY16$0−$14.7M
FY15$0−$23.4M
FY14$0−$21.9M
FY13--
Returned to shareholdersDividends paid and shares bought back
$0$2M$4M$6M$8MFY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearBuybacks
FY25-
FY24-
FY23-
FY22$6.8M
FY21-
FY20-
FY19-
FY18-
FY17-
FY16$229
FY15$38
FY14$2
FY13-